Pembrolizumab in combination with chemotherapy meets primary endpoints in phase III KEYNOTE-590 trial for first-line treatment of locally advanced or metastatic oesophageal cancer

Interim analysis of trial (n=749) of pembrolizumab in combination with chemotherapy (cisplatin plus 5-fluorouracil), met its primary endpoints of overall-and progression-free survival for first-line treatment of patients with locally advanced or metastatic oesophageal cancer.

Biospace Inc.